According to recent reports, Eli Lilly (LLY) is potentially planning to acquire French biotechnology company Abivax (ABVX). The news surfaced on December 22, sparking market speculation about the possible deal.
Abivax S.A., a France-based biotech firm, focuses on developing therapies for inflammatory diseases, immune disorders, and viral infections. Eli Lilly, a global pharmaceutical leader, has been actively expanding its portfolio through strategic acquisitions in the biotech space.
Further details regarding the potential acquisition, including deal terms and timelines, remain undisclosed at this stage.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments